Highlights Daxor Corporation Nyse

Equities

DXR

US2394671034

Real-time Estimate Cboe BZX Other stock markets 17:19:09 13/05/2024 BST			5-day change	1st Jan Change
9.625 ^USD	+0.76%		-3.32%	-0.49%

04-16	Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	CI
04-10	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	04-16	CI
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	04-10	CI
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	03-25	MT
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.	03-24	CI
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	03-11	CI
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	03-08	CI
Daxor Corporation Announces Two Significant New Customer Transactions with Daxor's BVA-100 in January 2024	02-12	CI
Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer	01-02	CI
Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers	11-13	CI
Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting	11/10/23	CI
Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®	10/08/23	CI
Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy	12/07/23	CI
Daxor Corporation Announces Further Acquisitions and Increased Utilization of Its Bva 100(R) Blood Volume Diagnostic Throughout the U.S	11/07/23	CI
Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients	23/03/23	CI
Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure	03/11/22	CI
Daxor Corporation Announces New Data from the Mayo Clinic in Rochester, NY Validating the Benefits of the company’s BVA-100 Blood Test for Patients with Heart Failure	04/10/22	CI
Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay for Heart Failure (HF) Patients	03/10/22	CI
Daxor Corporation Announces New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients with BVA-Guided Care	03/10/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Daxor Corporation Nyse

Equities

DXR

US2394671034

Highlights

Filters